Nom du produit:1-cyclopropylpiperazine

IUPAC Name:1-cyclopropylpiperazine

CAS:20327-23-5
Formule moléculaire:C7H14N2
Pureté:95%+
Numéro de catalogue:CM102401
Poids moléculaire:126.2

Unité d'emballage Stock disponible Prix($) Quantité
CM102401-10g in stock ƤȌ
CM102401-25g in stock ȷƤdž
CM102401-100g in stock ɐȷȦ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:20327-23-5
Formule moléculaire:C7H14N2
Point de fusion:-
Code SMILES:N1(C2CC2)CCNCC1
Densité:
Numéro de catalogue:CM102401
Poids moléculaire:126.2
Point d'ébullition:200°C at 760 mmHg
N° Mdl:MFCD06254805
Stockage:Store at 2-8°C.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Cyclopropanes
Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

Column Infos

RMC-9805
Revolution Medicines announced preliminary positive data for its RAS(ON) G12D-selective covalent inhibitor RMC-9805 in previously treated pancreatic ductal adenocarcinoma (PDAC) patients. The analysis showed that the disease control rate of PDAC patients treated with RMC-9805 was as high as 80%. RMC-9805 is a potential ‘first-in-class’ oral RAS(ON) G12D-selective inhibitor, that is being evaluated in trials to examine its efficacy and safety in patients with solid tumors carrying KRAS G12D mutations when used as a single agent or in combination with the pan-RAS inhibitor RMC-6236.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.